ArticleInsights into imaging2025
Transient hepatic intensity differences: correlations with treatment outcomes and adverse events following DEB-TACE in hepatocellular carcinoma.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTransient hepatic intensity differences (THID) on MRI are commonly observed in hepatocellular carcinoma (HCC) patients following drug-eluting bead transarterial chemoembolization (DEB-TACE). We evaluated the association between THID, treatment outcomes, and adverse events in HCC patients treated with DEB-TACE. MATERIALS AND
methodsThis retrospective analysis included data from a prospective study conducted with 102 consecutive HCC patients treated with DEB-TACE between December 2017 and December 2020. The chi-square test assessed correlations between THID and adverse events, including biliary injury, intrahepatic metastasis, and portal venous thrombosis. Kaplan-Meier method evaluated overall survival (OS) and progression-free survival (PFS), with log-rank tests comparing THID complexity (simple vs complex) and severity (mild, moderate, and severe). Logistic regression identified factors associated with THID development.
resultsAmong the 102 HCC patients, 74 (72.5%) developed THID after DEB-TACE. Patients with THID had significantly higher rates of biliary injury (47% vs 14.3%, p = 0.002) and intrahepatic metastasis (25.7% vs 7.1%, p = 0.030). Complex THID was associated with worse PFS (p = 0.024). Moderate-to-severe THID had worse OS (p = 0.019) and PFS (p = 0.038). Factors associated with THID development included a higher tumor burden, baseline THID, and Child-Pugh class A.
conclusionTHID correlates with an increased risk of biliary injury and intrahepatic metastasis and is associated with worse OS and PFS in HCC patients following DEB-TACE. CRITICAL RELEVANCE STATEMENT: THID development after DEB-TACE correlates with higher incidence of biliary injury, intrahepatic metastasis, and worse OS/PFS, emphasizing its potential as a critical imaging biomarker. This study advances clinical radiology by highlighting THID as an important factor in treatment outcomes. KEY POINTS: THID after drug-eluting bead transcatheter arterial chemoembolization correlates with treatment outcomes and adverse events in HCC. THID correlates with higher biliary injury, intrahepatic metastasis, and reduced survival rates. Complex or severe THID correlates with poorer survival in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.